Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases

Drug Metabolism Letters

Volumn 3, Issue 2, 2009, Pages 101-107

  Chang, Yan ^a   Moody, David E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Buprenorphine; Glucuronidation; Human liver microsome; LC MS MS; Nonspecific protein binding; UDP glucuronosyltransferase

Indexed keywords

BUPRENORPHINE; GLUCOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; NORBUPRENORPHINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ASSAY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

ANALGESICS, OPIOID; BUPRENORPHINE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MICROSOMES, LIVER; PROTEIN BINDING;

EID: 69949093628     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231209788654117     Document Type: Article

References (21)

1. Cowan, A.; Lewis, J.W.; MacFarlane, I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol., 1977, 60(4), 537-45.
2. Cone, E.; Gorodetzky, C.; Yousefnejad, D.; Buchwald, W.; Johnson, R. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos., 1984, 12(5), 577-81.
3. Iribarne, C.; Picart, D.; Dreano, Y.; Bail, J.-P.; Berthou, F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver micrsomes. Life Sci., 1997, 60(22), 1953-64.
4. Kobayashi, K.; Yamamoto, T.; Chiba, K.; Tani, M.; Shimada, N.; Ishizaki, T.; Kuroiwa, Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab. Dispos., 1998, 26(8), 818-21.
5. Moody, D.E.; Slawson, M.H.; Strain, E.C.; Laycock, J.D.; Spanbauer, A.C.; Foltz, R.L. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal. Biochem., 2002, 306(1), 31-9.
6. Picard, N.; Cresteil, T.; Djebli, N.; Marquet, P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos., 2005, 33(5), 689-95.
7. Chang, Y.; Moody, D.E.; McCance-Katz, E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos., 2006, 34(3), 440-8.
8. King, C.D.; Green, M.D.; Rios, G.R.; Coffman, B.L.; Owens, I.S.; Bishop, W.P.; Tephly, T.R. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys., 1996, 332(1), 92-100.
9. Coffman, B.L.; rios, G.R.; King, C.D.; Tephly, T.R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos., 1997, 25(1), 1-4.
10. Cheng, Z.; Radominska-Pandya, A.; Tephly, T.R. Cloning and expression of human UDP-glucuronosyltransferase (UGT) 1A8. Arch. Biochem. Biophys., 1998, 356(2), 301-5.
11. Coffman, B.L.; King, C.D.; Rios, G.R.; Tephly, T.R. The glucuronidation of opioids, other xenobiotics and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos., 1998, 26(1), 73-7.
12. Green, M.D.; King, C.D.; Mojarrabi, B.; MacKenzie, P.I.; Tephly, T.R. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos., 1998, 26(6), 507-12.
13. Cheng, Z.; Radominska-Pandya, A.; Tephly, T.R. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab. Dispos., 1999, 27(10), 1165-70.
14. Soars, M.G.; Ring, B.J.; Wrighton, S.A. The effect of incubation conditions on the enzyme kinetics of UDP-glucuonosyltransferases. Drug Metab. Dispos., 2003, 31(6), 762-7.
15. Obach, R.S. Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab. Dispos., 1997, 25(12), 1359-69.
16. Mohutsky, M.A.; Chien, J.Y.; Ring, B.J.; Wrighton, S.A. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. Pharmaceut. Res., 2006, 23(4), 654-62.
17. Huang, W.; Moody, D.E.; McCance-Katz, E.F. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther. Drug Monit., 2006, 28(2), 245-51.
18. Nelson, A.C.; Huang, W.; Moody, D.E. Variables in human liver microsome preparation: impact on the kinetics of l-α-acetylmethadol (LAAM) N-demethylation and dextromethorphan O-demethylation. Drug Metab. Dispos., 2001, 29(3), 319-25.
19. Motulsky, H.J.; Christopoulos, A. Fitting models to biological data using linear and nonlinear regression: A practical guide to curve fitting; GraphPad Software Inc.: San Diego, CA. 2003.
20. Fisher, M.B.; Campanale, K.; Ackermann, B.L.; Vandenbranden, M.; Wrighton, S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab. Dispos., 2000, 28(5), 560-6.
21. Uchaipichat, V.; Galetin, A.; Houston, J.B.; Mackenzie, P.I.; Williams, J.A.; Miners, J.O. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol. Pharmacol., 2008, 74(4), 1152-62.